

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS

Claims 1-23 (Cancelled)

Claim 24 (Previously Amended): A method for inhibiting an alloimmune response in a patient comprising the step of administering a therapeutically effective amount of a soluble 18KDa recombinant human CD40L consisting of amino acids 108 to 261 set forth in SEQ ID NO:1, containing the active binding site of CD40 and capable of binding thereto.

Claim 25 (Cancelled)

Claim 26 (Previously Added): The method of claim 24, wherein the alloimmune response is a human anti-HLA alloimmune response.

Claim 27 (Currently Amended): A method for inhibiting T Cell-cell function in an anti-HLA alloimmune response in a patient, comprising the step of administering a therapeutically effective amount of a soluble 18KDa recombinant human CD40L consisting of amino acids 108 to 261 of sequence set forth in SEQ ID NO:1 containing the active binding site of CD40 and capable of binding thereto.

Claim 28 (Cancelled)

Claim 29 (Cancelled)

Claim 30 (Currently Amended): The method of claim 27, for treating or preventing a disease selected from the group consisting of systemic lupus erythematosus (SLE), ~~sjögren's~~ Stjörge'n's syndrome, ~~sleroderma~~ scleroderma myositis, Raynaud's syndrome, type 1 diabetes, arthritis and rheumatoid arthritis, inflammatory bowel disease, uveitis, ~~myesthenia~~ myasthenia gravis, multiple sclerosis, idiopathic ~~thrombocytopenie~~ thrombocytopenia purpura and graft vs host disease as well as allergies which are dependent on T cells.

Claims 31-33 (Cancelled)